Zacks: Brokerages Anticipate Syneos Health Inc (NASDAQ:SYNH) Will Post Quarterly Sales of $1.18 Billion

Analysts expect Syneos Health Inc (NASDAQ:SYNH) to post sales of $1.18 billion for the current quarter, according to Zacks. Six analysts have made estimates for Syneos Health’s earnings, with the lowest sales estimate coming in at $1.18 billion and the highest estimate coming in at $1.19 billion. Syneos Health reported sales of $1.11 billion during the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The company is scheduled to announce its next earnings results on Tuesday, November 5th.

On average, analysts expect that Syneos Health will report full-year sales of $4.69 billion for the current year, with estimates ranging from $4.69 billion to $4.70 billion. For the next year, analysts forecast that the company will report sales of $5.00 billion, with estimates ranging from $4.95 billion to $5.06 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Syneos Health.

Syneos Health (NASDAQ:SYNH) last posted its earnings results on Tuesday, August 6th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.02. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Syneos Health had a return on equity of 9.82% and a net margin of 0.36%. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.62 EPS.

A number of brokerages have recently issued reports on SYNH. Zacks Investment Research upgraded Syneos Health from a “sell” rating to a “hold” rating in a research note on Friday, May 24th. KeyCorp upped their price objective on Syneos Health from $59.00 to $63.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Credit Suisse Group boosted their target price on Syneos Health from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Friday. Finally, SunTrust Banks boosted their target price on Syneos Health to $68.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $56.63.

NASDAQ SYNH traded down $1.34 during trading on Friday, hitting $49.84. The stock had a trading volume of 214,053 shares, compared to its average volume of 449,483. Syneos Health has a 12 month low of $36.26 and a 12 month high of $56.34. The company has a market capitalization of $5.38 billion, a PE ratio of 19.02, a P/E/G ratio of 1.82 and a beta of 1.53. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.89 and a current ratio of 0.89. The company’s 50-day moving average price is $49.83 and its two-hundred day moving average price is $48.22.

Several hedge funds have recently bought and sold shares of SYNH. Norges Bank bought a new position in Syneos Health in the fourth quarter worth $24,850,000. Geode Capital Management LLC lifted its position in Syneos Health by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 738,567 shares of the company’s stock worth $29,061,000 after purchasing an additional 50,175 shares during the period. Nisa Investment Advisors LLC bought a new position in Syneos Health in the first quarter worth $325,000. Strs Ohio lifted its position in Syneos Health by 1.4% in the first quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $1,516,000 after purchasing an additional 400 shares during the period. Finally, BB&T Corp lifted its position in Syneos Health by 7.4% in the first quarter. BB&T Corp now owns 8,093 shares of the company’s stock worth $418,000 after purchasing an additional 555 shares during the period.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

See Also: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.